Access BNP Assay
Access BNP reflects cardiac status and effects of therapy
Access BNP is used to aid in the diagnosis of heart failure and left ventricular dysfunction1. This high-performance assay can be used across all Beckman Coulter immunoassay analyzers, including, Access 2, DxI 600 and DxI 800.
B‐type natriuretic peptide (BNP) is a cardiac hormone originating in the heart2. In response to ventricular myocardium wall stress, pre-proBNP is synthesized and cleaved to proBNP, and finally cleaved to either the biologically inactive N-terminal piece of proBNP (NT-proBNP) or the biologically active BNP. In patients with heart failure, BNP levels are elevated3 and assessed as important measures of cardiac function and diagnosis of heart failure (HF)4.
This product may not be available in your country or region at this time. Please contact your Beckman Coulter sales representative or distributor for more information.
When every minute matters, Access BNP is the right assay for you
Laboratories can help clinicians deliver patient care with confidence for all stages of heart failure (HF) with Access BNP, a highly sensitive and specific assay that aids clinicians in the:
- Diagnosis and assessment of severity of congestive HF
- Risk stratification of patients with HF and acute coronary syndrome (ACS)
The Access BNP is a high-quality assay with an analytical sensitivity of 1 pg/mL. The assay demonstrates general specificity of 98%. BNP results less than or equal to 100 pg/mL are representative of normal values in patients without HF. BNP results greater than 100 pg/mL are considered abnormal and suggestive of patients with HF.
Beckman Coulter has produced BNP since 2003, which clinical laboratories have used under the brand name Quidel® Triage BNP Test for the Beckman Coulter Access Family of Immunoassay Systems. Beckman Coulter announced signing of a contract with Quidel on July 26, 2021*, and will eventually sell the product under the brand name Access BNP directly and through distributors to customers who will experience the same product quality, while gaining the convenience of direct contracting, ordering and support from Beckman Coulter.
| General Specificity |
98%, using threshold of 100 mL† |
| Analytical Measuring Range |
1 to 5000pg/mL |
| Sample Type/Size |
Plasma (EDTA) |
| Time to First Result |
≥16.2 minutes |
| Analytical Sensitivity |
1 mL (95% confidence) |
| Calibrator Levels |
0, and approximately 25, 100, 500, 2500, and 5000pg/mL |
| Open pack stability |
28 days |
| Calibration stability |
28 days |
| Total Imprecision |
<7% |
Available on These Analyzers
*The date for changing the brand name of the assay differs from region to region. Please contact your Beckman Coulter representative for more information.
†In the non-congestive heart failure population age 55 and older (95% confidence limit of BNP concentration)
1Bionda C, Bergerot C, Ardail D, Rodriguez-Lafrasse C, Rousson R. Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and clinical study. Ann Clin Lab Sci. 2006 Summer;36(3):299-306. PMID: 16951271.
2Weber, M., & Hamm, C. (2006). Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart (British Cardiac Society), 92(6), 843–849. https://doi.org/10.1136/hrt.2005.071233
3Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, et al. 2013 accf/aha guideline for the management of heart failure: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013;62:e147-239.
4Chien TI, Chen HH, Kao JT. Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. Clin Chim Acta. 2006 Jul 15;369(1):95-9. doi: 10.1016/j.cca.2006.01.017. Epub 2006 Mar 3. Erratum in: Clin Chim Acta. 2006 Oct;372(1-2):210. PMID: 16515777.
English
